Effects of Oyster Mushrooms on Cholesterol in HIV Patients
Author Information
Author(s): Donald I Abrams, Paul Couey, Starley B Shade, Mary Ellen Kelly, Nnemdi Kamanu-Elias, Paul Stamets
Primary Institution: University of California San Francisco
Hypothesis
Can Pleurotus ostreatus reduce non-HDL cholesterol levels in HIV-infected individuals taking antiretroviral therapy?
Conclusion
The study found that Pleurotus ostreatus did not significantly lower non-HDL cholesterol in HIV patients with ART-induced hypercholesterolemia.
Supporting Evidence
- Only 3 individuals achieved a sustained clinically significant decline in non-HDL cholesterol after 8 weeks.
- Mean non-HDL cholesterol was 204.5 mg/dL at the start and 200.2 mg/dL at the end of the study.
- Participants reported distaste for the mushroom preparation, which may have affected adherence.
Takeaway
The study tested if oyster mushrooms could help lower cholesterol in people with HIV, but it didn't work as hoped.
Methodology
A single-arm, open-label, proof-of-concept study over 8 weeks with 20 HIV-infected participants taking freeze-dried oyster mushrooms daily.
Potential Biases
Potential bias due to the open-label design and participant adherence issues.
Limitations
The study had a small sample size and only a few participants achieved significant cholesterol reduction.
Participant Demographics
Mostly male (96%), Caucasian (68%), mean age 46.4 years, with an average of 13.7 years of HIV infection.
Statistical Information
Confidence Interval
95% CI = -17.4, 14.0 for non-HDL cholesterol change
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website